FindTrial
Sign In

The Exploration of the Efficacy of Metformin Combined with First-line Chemotherapy for the Treatment of Ovarian Cancer

The Exploration of the Efficacy of Metformin Combined with First-line Chemotherapy for the Treatment of Ovarian Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17011859
Enrollment
Unknown
Registered
2017-07-04
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

optimal cytoreductive surgery group:TC
optimal cytoreductive surgery group:TC+metformin
non-optimal cytoreductive surgery group:TC
non-optimal cytoreductive surgery group? :TC+metformin

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. epithelial ovarian cancer including serous carcinoma, mucous carcinoma, endometriod carcinoma and clear cell carcinoma; 2. aged 18-75 years; 3. normal liver and renal function:ALT<66 U/L, AST<36 U/L, total bilirubin<22 umol/L, crea<106 umol/L, urea nitrogen<6.1 mmol/L; 4. normal bone marrow function: neutrophil =1800/mm3, platelets=100,000/mm3.

Exclusion criteria

Exclusion criteria: 1. history of radiotherapy or chemotherapy; 2. history of tumors; 3. pregnency; 4. mental disorders; 5. history of diabetes mellitus; 6. contraindications of metformin.

Design outcomes

Primary

MeasureTime frame
response rate;progression free survival;—

Secondary

MeasureTime frame
toxic and side effects;—

Countries

China

Contacts

Public ContactHong Sun

Obstetrics and Gynecology Hospital of Fudan University

hongsun57@hotmail.com+86 13801951021

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026